| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Zingiberen Newsaponin targets multiple pathways. It is a potent inhibitor of the AKR1C1/JAK2/STAT3 and NF-κB signaling pathways. It also induces platelet aggregation. By inhibiting these pathways, it promotes cancer cell apoptosis through the induction of oxidative stress, as evidenced by the upregulation of ROS and MDA levels.
|
|---|---|
| ln Vitro |
In vitro, Zingiberen Newsaponin exhibits induction effect on platelet aggregation. It inhibits the proliferation of a panel of established human and murine cancer cell lines. It promotes cancer cell apoptosis through the induction of oxidative stress.
|
| ln Vivo |
In vivo, Zingiberen Newsaponin is a bioactive compound with potential applications in cancer research and thrombosis研究. Its ability to induce platelet aggregation and inhibit cancer cell proliferation makes it a compound of interest for studying these processes.
|
| Enzyme Assay |
The in vitro platelet aggregation assay for Zingiberen Newsaponin involves incubating platelet-rich plasma with the compound and measuring aggregation using a platelet aggregometer. The induction of aggregation is quantified.
|
| Cell Assay |
In vitro cell culture studies for Zingiberen Newsaponin utilize cancer cell lines to study its antiproliferative effects. Cells are treated with the compound, and cell viability is assessed by MTT assays. Apoptosis is detected by measuring ROS and MDA levels.
|
| Animal Protocol |
In vivo animal experiments for Zingiberen Newsaponin are not extensively documented. Its effects on platelet aggregation could be studied in animal models of thrombosis. Its anticancer effects could be studied in xenograft models.
|
| ADME/Pharmacokinetics |
Zingiberen Newsaponin has a molecular weight of 1047.18 g/mol and is soluble in DMSO. It is typically stored as a powder at -20°C. Its purity is ≥97%.
|
| Toxicity/Toxicokinetics |
Toxicological data for Zingiberen Newsaponin are limited, as it is a research compound. Its ability to induce platelet aggregation suggests it could have pro-thrombotic effects. It is not intended for human use. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
Curcumin has been reported in yam, hairy yam, and other organisms with available data.
Zingiberen Newsaponin is a research compound with no clinical approval. It is a valuable tool for studying platelet aggregation, cancer cell proliferation, and the AKR1C1/JAK2/STAT3 and NF-κB signaling pathways. |
| Molecular Formula |
C51H82O22
|
|---|---|
| Molecular Weight |
1047.1836
|
| Exact Mass |
1046.529
|
| CAS # |
91653-50-8
|
| PubChem CID |
102475150
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
285-287 °C (methanol)
|
| Index of Refraction |
1.637
|
| LogP |
4.38
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
22
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
73
|
| Complexity |
1940
|
| Defined Atom Stereocenter Count |
31
|
| SMILES |
C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O)O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O)C)C)C)OC1
|
| InChi Key |
XJOTXMLDNWCDRH-HAUZKCKMSA-N
|
| InChi Code |
InChI=1S/C51H82O22/c1-20-8-13-51(64-19-20)21(2)32-28(73-51)15-27-25-7-6-23-14-24(9-11-49(23,4)26(25)10-12-50(27,32)5)66-48-44(72-45-38(60)36(58)33(55)22(3)65-45)40(62)42(31(18-54)69-48)70-47-41(63)43(35(57)30(17-53)68-47)71-46-39(61)37(59)34(56)29(16-52)67-46/h6,20-22,24-48,52-63H,7-19H2,1-5H3/t20-,21+,22+,24+,25-,26+,27+,28+,29-,30-,31-,32+,33+,34-,35-,36-,37+,38-,39-,40+,41-,42-,43+,44-,45+,46+,47+,48-,49+,50+,51-/m1/s1
|
| Chemical Name |
(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)-2-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9549 mL | 4.7747 mL | 9.5495 mL | |
| 5 mM | 0.1910 mL | 0.9549 mL | 1.9099 mL | |
| 10 mM | 0.0955 mL | 0.4775 mL | 0.9549 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.